Copper-64 (t(1/2)=12.7h; beta(+): 0.653 MeV, 17.4%; beta(-): 0.578 MeV, 39%) is produced in a biomedical cyclotron and has applications in both imaging and therapy. Macrocyclic chelators are widely used as bifunctional chelators to bind copper radionuclides to antibodies and peptides owing to their relatively high kinetic stability. A novel side-bridged cyclam featuring both pendant acetate and phosphonate groups was synthesized using a Kabachnik-Fields approach followed by hydrobromic acid deprotection. The Cu(II) complex of the novel ligand was synthesized, radiolabeling with (64)Cu was demonstrated, and in vitro (serum) stability was performed. In addition, in vivo distribution and clearance of the (64)Cu-labeled complex was visualized by positron emission tomography (PET) imaging. This novel chelate may be useful in (64)Cu-mediated diagnostic positron emission tomography (PET) imaging as well as targeted radiotherapeutic applications.
Copper-64 (t(1/2)=12.7h; n>an class="Chemical">beta(+): 0.653 MeV, 17.4%; beta(-): 0.578 MeV, 39%) is produced in a biomedical cyclotron and has applications in both imaging and therapy. Macrocyclicchelators are widely used as bifunctional chelators to bind copper radionuclides to antibodies and peptides owing to their relatively high kinetic stability. A novel side-bridged cyclam featuring both pendant acetate and phosphonate groups was synthesized using a Kabachnik-Fields approach followed by hydrobromic acid deprotection. The Cu(II)complex of the novel ligand was synthesized, radiolabeling with (64)Cu was demonstrated, and in vitro (serum) stability was performed. In addition, in vivo distribution and clearance of the (64)Cu-labeled complex was visualized by positron emission tomography (PET) imaging. This novel chelate may be useful in (64)Cu-mediated diagnostic positron emission tomography (PET) imaging as well as targeted radiotherapeutic applications.
Authors: Ramunas J. Motekaitis; Buck E. Rogers; David E. Reichert; Arthur E. Martell; Michael J. Welch Journal: Inorg Chem Date: 1996-06-19 Impact factor: 5.165
Authors: Silvia Füzerová; Jan Kotek; Ivana Císarová; Petr Hermann; Koen Binnemans; Ivan Lukes Journal: Dalton Trans Date: 2005-07-26 Impact factor: 4.390
Authors: C J Anderson; F Dehdashti; P D Cutler; S W Schwarz; R Laforest; L A Bass; J S Lewis; D W McCarthy Journal: J Nucl Med Date: 2001-02 Impact factor: 10.057
Authors: B E Rogers; C J Anderson; J M Connett; L W Guo; W B Edwards; E L Sherman; K R Zinn; M J Welch Journal: Bioconjug Chem Date: 1996 Jul-Aug Impact factor: 4.774
Authors: Jan Kotek; Premysl Lubal; Petr Hermann; Ivana Císarová; Ivan Lukes; Tomás Godula; Ivona Svobodová; Petr Táborský; Josef Havel Journal: Chemistry Date: 2003-01-03 Impact factor: 5.236
Authors: Jeffrey N Bryan; Fang Jia; Huma Mohsin; Geethapriya Sivaguru; Carolyn J Anderson; William H Miller; Carolyn J Henry; Michael R Lewis Journal: Cancer Biol Ther Date: 2011-06-15 Impact factor: 4.742
Authors: Riccardo Ferdani; Dannon J Stigers; Ashley L Fiamengo; Lihui Wei; Barbara T Y Li; James A Golen; Arnold L Rheingold; Gary R Weisman; Edward H Wong; Carolyn J Anderson Journal: Dalton Trans Date: 2011-12-15 Impact factor: 4.390